Skip to main content
TipRanks
Go Ultimate75% OFF

Tsubota Laboratory Incorporated (4890) AI Stock Analysis

1 Followers
JP:4890

Tsubota Laboratory Incorporated

(TSE/TYO:4890)

Select Model
Rating:38Underperform
Price Target:JPY 189.00â–¼(-5.03% Downside)
Action:reiterated
Date:10/25/26

Tsubota Laboratory faces critical headwinds, reflected in an exceptionally weak overall score. The collapse in revenue, massive operating losses, and accelerating cash burn severely impair its financial foundation. Compounded by deeply negative valuation metrics and bearish technical momentum, the stock carries substantial downside risk, mitigated only slightly by a conservative debt profile.

Positive Factors
Low Leverage and Capital CushionThe conservatively financed balance sheet provides a meaningful cushion while operating results fluctuate. Low leverage reduces dependence on borrowing and limits balance-sheet pressure, giving the company more flexibility to absorb losses or pursue ophthalmology-related development over the next several quarters.
Negative Factors
Severe Revenue ContractionThe sharp 2026 revenue contraction is a major threat to the company’s durable earnings base. Such a steep decline can weaken market reach, reduce operating leverage, and make it difficult for the existing business model to cover costs consistently over the next several quarters.

Tsubota Laboratory Incorporated (4890) vs. iShares MSCI Japan ETF (EWJ)

-60%-40%-20%0%20%40%JP:4890-45.18%EWJ+15.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 5.11B
Dividend Yield
―
Average Volume (3M)
39.22K
Price to Earnings (P/E)
-7.2
Beta (1Y)
0.33
Revenue Growth
-39.46%
EPS Growth
-317.84%
Country
Japan
Employees
22
Sector
Healthcare
Sector Strength
51
Industry
Specialty Business Services

Tsubota Laboratory Incorporated Business Overview & Revenue Model

Company Description

Operating from Tokyo, Japan since its establishment in 2012, Tsubota Laboratory Incorporated is dedicated to the research and development of pharmaceutical products and medical devices, specifically targeting the treatment of myopia, dry eyes, and pr...

How the Company Makes Money

The company primarily makes money by commercializing ophthalmology-related offerings, which typically includes monetization from product and/or service sales tied to eye-care solutions and potentially revenues associated with research and development...

Tsubota Laboratory Incorporated Financial Statement Overview

Summary

Severe financial deterioration is evident with revenue plummeting 85.3% and net income swinging to a massive 761 million loss. Despite a negligible debt burden, accelerating cash burn and deeply negative cash flows present substantial liquidity risks.

Income Statement

15Very Negative

Balance Sheet

55Neutral

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue390.58M200.02M1.36B673.53M954.69M640.92M
Gross Profit148.27M131.57M1.15B-9.48M686.83M528.76M
EBITDA-720.42M-765.24M262.46M-609.24M206.22M173.87M
Net Income-693.63M-761.82M205.77M-641.32M90.18M153.32M
Balance Sheet
Total Assets1.31B1.32B2.50B2.30B2.67B1.62B
Cash, Cash Equivalents and Short-Term Investments699.26M969.85M1.54B1.88B2.16B1.17B
Total Debt63.64M69.21M90.38M116.90M139.34M223.82M
Total Liabilities578.57M454.92M915.85M927.93M722.59M873.44M
Stockholders Equity733.83M863.86M1.59B1.37B1.95B744.35M
Cash Flow
Free Cash Flow0-586.61M-331.75M-313.35M-15.27M582.69M
Operating Cash Flow0-577.83M-317.75M-301.35M28.49M654.91M
Investing Cash Flow0-8.41M-14.55M-12.00M-54.03M-72.23M
Financing Cash Flow017.23M-12.25M35.74M1.01B-18.53M

Tsubota Laboratory Incorporated Technical Analysis

Technical Analysis SentimentNegative
Last Price199.00

Price Trends

50DMA253.88Negative
100DMA253.26Negative
200DMA272.47Negative

Market Momentum

MACD-11.98Positive
RSI26.88Positive
STOCH6.47Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4890, the sentiment is Negative. The current price of 199.00 is below the 20-day moving average (MA) of 237.10, below the 50-day MA of 253.88, and below the 200-day MA of 272.47, indicating a bearish trend. The MACD of -11.98 indicates Positive momentum. The RSI at 26.88 is Positive, neither overbought nor oversold. The STOCH value of 6.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4890.

Tsubota Laboratory Incorporated Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4890 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:9989JP:998982OutperformJPY 492.95B15.6111.04%3.13%3.99%-0.48%
JP:3391JP:339181OutperformJPY 1.14T19.857.13%1.85%――
JP:7649JP:764969NeutralJPY 555.74B17.689.94%1.22%8.97%-29.54%
JP:3549JP:354967NeutralJPY 492.42B25.84―0.29%12.54%15.87%
JP:3349JP:334960NeutralJPY 520.98B16.15―1.25%8.99%3.61%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4890JP:489038UnderperformJPY 5.22B-7.17――-39.46%-317.84%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%20%JP:4890JP:9989JP:7649JP:3391JP:3349JP:3549Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4890 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4890Tsubota Laboratory Incorporated199.00-171.00-46.22%
JP:9989Sundrug Co 4152.00-6.76-0.16%
JP:7649Sugi Holdings Co 1408.50-394.14-21.86%
JP:3391TSURUHA Holdings 2469.50-299.95-10.83%
JP:3349COSMOS Pharmaceutical Corporation6371.00-969.33-13.21%
JP:3549KUSURI NO AOKI HOLDINGS CO.,LTD.4949.001081.6827.97%

Tsubota Laboratory Incorporated Corporate Events

Tsubota Laboratory Reports ¥491 Million Six-Month Revenue and Operating Loss

Nov 12, 2026

Tsubota Laboratory Incorporated, listed on the Tokyo Stock Exchange under code 4890, reported consolidated revenue of ¥491 million for the six months ended September 30, 2026, alongside an operating loss of ¥331 million, an ordinary loss of ¥294 mill...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 25, 2026